Fingolimod

Chemical formula: C₁₉H₃₃NO₂  Molecular mass: 307.471 g/mol  PubChem compound: 107970

Therapeutic indications

Fingolimod is indicated for:

Relapsing remitting multiple sclerosis

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 - 65 years old)

Fingolimod is indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult patients and paediatric patients aged 10 years and older:

  • Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy.

or

  • Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Fingolimod is contraindicated in the following cases:

Severe cardiac arrhythmias

Arrhythmia

Pregnancy

Pregnancy

Immunodeficiency syndrome

AIDS

Immunocompromised patients

Immunodeficiency

Infections

Infectious disease

Malignancies

Malignant tumour

Severe liver impairment (Child-Pugh class C)

Hepatic failure stage IV

Myocardial infarction, unstable angina pectoris, stroke, transient ischaemic attack, class III/IV heart failure

at least one of
Myocardial infarction
Preinfarction syndrome
CVA - Cerebrovascular accident
Temporary cerebral vascular dysfunction
Decompensated cardiac failure
Heart failure New York Heart Assosiation Class IΙΙ
Heart failure New York Heart Assosiation Class IV

QTc interval ≥500 msec

at least one of
Long QT syndrome
Prolonged QT interval

Second-degree Mobitz type II catrioventricular block, third-degree AV block, sick-sinus syndrome

at least one of
Mobitz type II atrioventricular block
Complete atrioventricular block
Sick sinus syndrome

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: GILENYA Hard capsule
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈